Vor Biopharma Inc. VOR shares are trading higher on Friday after the company announced it has entered into a securities purchase agreement for a private investment in public equity financing (PIPE).

Vor Biopharma Inc.周五，Vor股价上涨，此前该公司宣布已签署一项证券购买协议，用于私人投资于公共股权融资（PIPE）。

What To Know: The company expects to generate about $55.6 million in gross proceeds from the PIPE. Vor plans to utilize these proceeds in order to fund clinical and preclinical development of its pipeline candidates and for general corporate purposes.

需要知道的是：该公司预计该管道将产生约5560万美元的总收益。Vor计划利用这些收益为其候选管道的临床和临床前开发以及一般企业用途提供资金。

As part of the PIPE, Vor will issue a total of 55,871,260 shares of common stock and accompanying warrants to purchase an additional 69,839,075 shares, priced at $0.99425 per share and warrants.

作为PIPE的一部分，Vor将发行总计55871260股普通股和附带的认股权证，以额外购买69839075股，每股价格为0.99425美元。

If exercised for cash, the warrants would result in additional gross proceeds to Vor of up to approximately $58.5 million.

如果以现金形式行使，认股权证将为Vor带来额外的总收益，高达约5850万美元。

The PIPE was led by Reid Hoffman who believes in the potential of Vor’s trem-cel therapy to treat acute myeloid leukemia. The therapy utilizes CRISPR/cas9 to modify the bone marrow of patients.

管道由里德·霍夫曼领导，他相信Vor的trem-cel疗法治疗急性髓细胞白血病的潜力。该疗法利用CRISPR/cas9修饰患者的骨髓。

“Early data released by Vor suggest a potent effect, which now must be confirmed by future trials. I am delighted to support this company that uses a game-changing technology that will hopefully impact the lives of patients with this lethal cancer – but even more the trajectory of cancer therapy in general,” said Hoffman..

霍夫曼说：“Vor发布的早期数据表明，它具有强大的作用，现在必须通过未来的试验来证实。我很高兴支持这家公司，它使用一种改变游戏规则的技术，有望影响这种致命癌症患者的生活，但更大程度上影响癌症治疗的总体轨迹。”。。

Related Link: Spotlight on SolarEdge Technologies: Analyzing the Surge in Options Activity

相关链接：聚焦SolarEdge技术：分析期权活动激增

VOR Price Action: At the time of writing, Vor stock is trading 40.8% higher at $1.18, according to data from Benzinga Pro.

VOR价格行动：根据Benzinga Pro的数据，在撰写本文时，VOR股价上涨40.8%，收于1.18美元。

Image: Image: Emilian Danaila from PixabayVORVor Biopharma Inc$1.2144.3%WatchlistOverviewMarket News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

图片：图片：PixabayVORVor Biopharma Inc.的Emilian Danaila$1.2144.3%观察列表概述Benzinga API©2024 Benzinga.com为您带来的市场新闻和数据。Benzinga不提供投资建议。保留所有权利。